Bayer’s asundexian has won FDA approval to reduce the risk of stroke in people who recently had a mild-to-moderate non-cardio-embolic ischaemic stroke or a high-risk transient ischaemic attack, reports Endpoints News.
The agency gave the green light to the drug in combination with standard-of-care antiplatelet therapy. Asundexian will be sold under the brand name Sunharbo, with a list price of $748.50 for a 30-day supply.
Sunharbo is the first factor XIa inhibitor to win approval.
“The milestone marks progress in [the stroke] space that we haven’t seen in the past 15 to 20 years,” said Sara Hegab, Bayer’s head of stroke and thrombosis in the US, while analysts predict asundexian could reach $3.4bn in peak sales.
The FDA’s decision was based on positive data from a phase 3 trial called OCEANIC-STROKE, in which Sunharbo, added to antiplatelet therapy, slashed the occurrence of ischaemic stroke by 26% compared with antiplatelet therapy alone. The study enrolled more than 12 000 people who had a non-cardio-embolic ischaemic stroke or high-risk transient ischaemic attack within the preceding 72 hours.
“Antiplatelet therapies can’t always be used long term due to their risk of bleeding,” Hegab said.
Sunharbo blocks an enzyme that plays a key role in excessive blood clotting but not so much in the body’s normal physiological healing mechanisms, which means there’s a much lower risk of bleeding side effects, she added.
In OCEANIC-STROKE, rates of major bleeding events were similar between the treatment (1.9%) and placebo (1.7%) arms.
However, the FDA noted major bleeding was higher with Sunharbo in patients over 75 and during the first 90 days of treatment, and gastrointestinal bleeding was more common than with placebo. The drug is not approved for preventing strokes in patients with atrial fibrillation.
The approval also bodes well for other candidates with the same target, including Bristol Myers Squibb and Johnson & Johnson’s milvexian and Novartis’s abelacimab, both of which are in phase 3 development.
Bayer estimates that about 795 000 people have a stroke in the US each year, with about 20% to 30% of these events being recurrent strokes.
See more from MedicalBrief archives:
New blood-thinner cuts TIA risk – global trial
AI helps drugmakers slash clinical trial costs and time
